Exelixis plans an NDA filing for zanzalintinib after detailed STELLAR‑303 data showed an overall survival benefit when combined with Roche’s atezolizumab in previously treated metastatic colorectal cancer, the company said. Investigators presented the dataset at ESMO and published detailed results in The Lancet. Company statements described a 20% reduction in risk of death in the intent‑to‑treat population and consistent effects across prespecified subgroups. Exelixis signalled intent to file with regulators before year‑end based on the phase 3 readout and will include the survival dataset in regulatory communications. Analysts and clinicians noted the benefit was modest in absolute terms and investor reaction was mixed, reflecting expectations around magnitude of effect, safety profile and competitive third‑line options. Exelixis said the data will underpin a submission aimed at expanding third‑line treatment choices for hard‑to‑treat colorectal cancer.